U2AF35B Antibody

How do I validate the specificity of U2AF35B antibodies in isoform-specific experiments?

• Methodological approach:

  • Perform siRNA-mediated knockdown of U2AF35 isoforms (a and b) in HEK293 cells and monitor antibody reactivity via western blot (WB). Specificity is confirmed if signal reduction correlates with isoform depletion (∼90% knockdown efficacy) .

  • Use isoform-specific small interfering RNAs (siRNAs) or splice-switching oligonucleotides (SSOs) to perturb U2AF35a/b ratios, followed by immunoprecipitation (IP)-WB to assess cross-reactivity .

  • Compare antibody performance across cell lines with known U2AF35 expression levels (e.g., HEK-293, Ramos, HSC-T6) using knockout (KO) controls .

What experimental designs optimize U2AF35B detection in splicing regulation studies?

• Key considerations:

  • Timing: Maximize antibody sensitivity by harvesting cells 72–96 hours post-siRNA transfection, when isoform depletion peaks .

  • Crosslinking: Use formaldehyde fixation for chromatin-bound U2AF35B in nascent RNA splicing assays .

  • Multi-application validation: Combine IP with RNA-seq to link U2AF35B occupancy to splicing outcomes (e.g., PFN2 intron 2 3′ss selection) .

How do U2AF35B-specific antibodies resolve functional antagonism between U2AF35 isoforms?

• Experimental framework:

  • Express epitope-tagged U2AF35a/b in U2AF35-depleted cells and perform RNA immunoprecipitation (RIP)-seq. Monitor isoform-specific binding to exons with divergent 3′ss features (e.g., weak polypyrimidine tracts) .

  • Quantify rescue efficiency of splicing defects using mutants (e.g., Q157R, Q157Rdel) via minigene reporters. For example:

• Pair antibody-based IP with mass spectrometry to identify isoform-specific interactors (e.g., PUF60 for U2AF35a, CAPERα for U2AF35b) .

How to troubleshoot contradictions in U2AF35B-dependent splicing data?

• Common pitfalls and solutions:

  • Off-target antibody binding: Validate using KO cell lines and orthogonal methods (e.g., CRISPR-Cas9 editing followed by RNA-seq) .

  • Compensatory mechanisms: Monitor U2AF2 expression, which increases 2-fold upon U2AF35 depletion .

  • Cryptic splice site activation: Use high-depth RNA-seq (≥68M reads/sample) and branch point analysis to distinguish direct vs. indirect effects .

What methodologies elucidate U2AF35B’s role in alternative polyadenylation (APA)?

• Stepwise protocol:

  • Perform 3′READS or PAS-seq on U2AF35B-depleted cells to identify intronic APA shifts (e.g., U2AF1 transcripts) .

  • Use antibody-based chromatin isolation RNA-seq (ChIRP) to map U2AF35B occupancy near APA sites.

  • Correlate U2AF35B binding with polII phosphorylation status (e.g., CTD Ser2/5 levels) to assess transcriptional coupling .

How to design crosslinking experiments for U2AF35B-RNA interaction mapping?

• Advanced workflow:

  • UV crosslink cells at 254 nm (150 mJ/cm²) to stabilize RNA-protein interactions.

  • Immunoprecipitate U2AF35B using Protein A/G magnetic beads and stringent wash buffers (e.g., 300 mM NaCl, 0.1% SDS) .

  • Library preparation for CLIP-seq with RNase I/T1 digestion to resolve binding sites at 20–50 nt resolution.

  • Critical controls: Include IgG-isotype controls and RNase-treated samples to exclude non-specific RNA associations .